Clearmind Medicine Inc. has announced the successful completion of patient recruitment for the first segment of Part B of its CMND-100 Phase I/IIa clinical trial, which focuses on Alcohol Use Disorder (AUD). This development is crucial as the company transitions from testing in healthy volunteers to a patient population that is significantly impacted by addiction.
Located in Vancouver, British Columbia, Clearmind Medicine Inc. operates within the pharmaceutical preparations sector (SIC 2834). The company is publicly traded on Nasdaq under the ticker CMND. Clearmind is dedicated to developing non-hallucinogenic psychedelic-derived neuroplastogens aimed at treating neuropsychiatric, metabolic, and addiction disorders.
According to the recent filing dated October 27, 2026, Clearmind's press release highlighted that the trial's Part B consists of two sequential single-dose ascending cohorts, evaluating 80 mg and 160 mg doses of CMND-100 in patients diagnosed with moderate-to-severe AUD. The trial is being conducted at prestigious clinical sites, including Johns Hopkins University School of Medicine and Yale School of Medicine.
Dr. Adi Zuloff-Shani, CEO of Clearmind, stated, "Completing recruitment for the first portion of Part B marks a significant advancement for our CMND-100 clinical program, as we transition from healthy volunteers to the very patient population we aim to impact." This statement reflects the company's commitment to addressing a major health issue and the potential for CMND-100 to provide therapeutic benefits.
The completion of patient recruitment may impact various stakeholders, including the patients involved in the trial, healthcare providers, and investors looking for innovative solutions in the treatment of AUD. The pharmaceutical industry, particularly those focusing on addiction therapies, will closely monitor the outcomes of this trial.
The filing does not specify what happens next, but it is expected that Clearmind will continue to advance its clinical program and share results as they become available.